Nordisk Acquires Ziylo’s Glucose Binding Platform to Expand its Glucose Responsive Insulins

 Nordisk Acquires Ziylo’s Glucose Binding Platform to Expand its Glucose Responsive Insulins

Nordisk Acquires Ziylo’s Glucose Binding Platform to Expand its Glucose Responsive Insulins

Shots:
  • Novo has acquired Ziylo to develop glucose responsive insulins, leading to a better metabolic control and reducing diabetic rates
  • Novo has paid an upfront payment to Ziylo ~$800 mn and earn-outs with possibility of milestone payments
  • In an ongoing deal, Novo has a research collaboration with Carbometrics, to develop glucose responsive insulins

Click here to read full press release/ article | Ref: Novo Nordisk | Image:  PRNewsWire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post